Wedbush analyst David Nierengarten says Dendreon's (DNDN +4.2%) chances with Provenge in the EU...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Wedbush analyst David Nierengarten says Dendreon's (DNDN +4.2%) chances with Provenge in the EU are practically zero. While the EMA is likely to grant approval, Nierengarten asks "Who's going to make it?" He points out that no European manufacturer has yet stepped up to work with the company. "All-in," he concludes, "we do not estimate any sales for Provenge in the EU, and we do not believe the European opportunity, if there is one, would be profitable in any significance."